329871 Erythropoietin, Human, Recombinant, CHO Cells

329871
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      329871-50UG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Plastic ampoule 50 μg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewRecombinant, human erythropoietin (EPO) expressed in CHO cells. EPO is a glycoprotein produced by the kidneys and is involved in red blood cell production. It has a predicted molecular mass of ~21 kDa but migrates at ~37 kDa on SDS-PAGE.
          Sialic acid content: > 10 moles/mole of protein.
          Catalogue Number329871
          Brand Family Calbiochem®
          SynonymsEPO, Erythropoietin-α
          References
          ReferencesFrank, S.J. 2002. Endocrinology 143, 2.
          Cerami, A. 2001. Semin. Hematol. 38, 33.
          Donnelly, S. 2001. Am. J. Kidney Dis. 38, 415.
          Goodnough, L.T. 2001. Curr. Opin. Hematol. 8, 405.
          Jelkmann, W, and Hellwig-Burgel, T. 2001. Adv. Exp. Med. Biol. 502, 169.
          Siren, A.L., and Ehrenreich, H. 2001. Eur. Arch. Psychiatry Clin. Neurosci 251, 179.
          Hansson, G.K., et al. 1992. Scand. J. Clin. Lab. Invest. 52, 35.
          Lee, L.G., et al. 1986. Cytometry 7, 35.
          Product Information
          CAS number11096-26-7
          FormLiquid
          FormulationIn 300 mM NaCl, 20 mM Na/K phosphate, pH 7.5.
          Applications
          Biological Information
          Purity≥98% by HPLC
          Specific Activity≥1.0 X 10⁵ IU/mg protein
          Concentration Label Please refer to vial label for lot-specific concentration
          Physicochemical Information
          ContaminantsEndotoxin: <10 EU/10 µg protein
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          RTECSKF5885000
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Blue Ice Only
          Toxicity Standard Handling
          Storage -20°C
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution refrigerate (4°C) for short-term storage or aliquot and freeze (-20°C or -70°C) for long-term storage. Stock solutions are stable for up to 1 month at 4°C, up to 3 months at -20°C, or up to 6 months at -70°C. Avoid freeze/thaw cycles of solutions.
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          329871

          References

          Reference overview
          Frank, S.J. 2002. Endocrinology 143, 2.
          Cerami, A. 2001. Semin. Hematol. 38, 33.
          Donnelly, S. 2001. Am. J. Kidney Dis. 38, 415.
          Goodnough, L.T. 2001. Curr. Opin. Hematol. 8, 405.
          Jelkmann, W, and Hellwig-Burgel, T. 2001. Adv. Exp. Med. Biol. 502, 169.
          Siren, A.L., and Ehrenreich, H. 2001. Eur. Arch. Psychiatry Clin. Neurosci 251, 179.
          Hansson, G.K., et al. 1992. Scand. J. Clin. Lab. Invest. 52, 35.
          Lee, L.G., et al. 1986. Cytometry 7, 35.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision19-November-2007 JSW
          SynonymsEPO, Erythropoietin-α
          DescriptionRecombinant, human erythropoietin (EPO) expressed in CHO cells. EPO is a glycoprotein hormone produced by the kidneys that is involved in the survival, growth, and differentiation of erythroid precursor cells. Stimulation of erythropoiesis involves the binding of EPO to the extracellular domain of the EPO receptor (EPOR) and triggering of intracellular signaling events, including phosphorylation of the receptor and activation of the JAK-STAT, RAS, and PI3-kinase pathways. Reported to act as a neuroprotective agent. Expressed in and purified from CHO cells. The predicted molecular weight is ~21 kDa, but it migrates at ~37 kDa on SDS-PAGE. Sialic acid content: > 10 moles/mole of protein. Sialic acid content: > 10 moles/mole of protein.
          FormLiquid
          FormulationIn 300 mM NaCl, 20 mM Na/K phosphate, pH 7.5.
          Concentration Label Please refer to vial label for lot-specific concentration
          CAS number11096-26-7
          RTECSKF5885000
          Purity≥98% by HPLC
          ContaminantsEndotoxin: <10 EU/10 µg protein
          Specific activity≥1.0 X 10⁵ IU/mg protein
          SolubilityReconstitute with 500 µl H₂O or aqueous buffer.
          Storage -20°C
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution refrigerate (4°C) for short-term storage or aliquot and freeze (-20°C or -70°C) for long-term storage. Stock solutions are stable for up to 1 month at 4°C, up to 3 months at -20°C, or up to 6 months at -70°C. Avoid freeze/thaw cycles of solutions.
          Toxicity Standard Handling
          Merck USA index14, 3688
          ReferencesFrank, S.J. 2002. Endocrinology 143, 2.
          Cerami, A. 2001. Semin. Hematol. 38, 33.
          Donnelly, S. 2001. Am. J. Kidney Dis. 38, 415.
          Goodnough, L.T. 2001. Curr. Opin. Hematol. 8, 405.
          Jelkmann, W, and Hellwig-Burgel, T. 2001. Adv. Exp. Med. Biol. 502, 169.
          Siren, A.L., and Ehrenreich, H. 2001. Eur. Arch. Psychiatry Clin. Neurosci 251, 179.
          Hansson, G.K., et al. 1992. Scand. J. Clin. Lab. Invest. 52, 35.
          Lee, L.G., et al. 1986. Cytometry 7, 35.